The potential of erythropoietin to treat asphyxia in newborns

Gillian C Pet
Sandra E Juul
Department of Pediatrics, Division of Neonatology, University of Washington, Seattle, WA, USA

Abstract:
Perinatal asphyxia is a cause of significant neonatal morbidity worldwide. Lack of oxygenation and perfusion to the neonatal brain leads to energy failure and cell death. Currently, therapeutic hypothermia is the standard of care for term infants with hypoxic-ischemic encephalopathy, but as it has shown only modest effects on survival and morbidity, additional neuroprotective agents are needed. Erythropoietin has been extensively studied as a neuroprotective agent for infants who suffer a hypoxic-ischemic brain injury. It has multiple mechanisms of action, in both preventing cell death and promoting tissue repair. Studies have progressed over time from in vitro to in vivo studies, first in animals and now in humans, with several Phase I/II trials completed and Phase III trials underway. As therapeutic hypothermia has become the standard of care in treating term infants with hypoxic-ischemic encephalopathy, studies must now evaluate other neuroprotective agents, including erythropoietin, used in concert with therapeutic hypothermia. Erythropoietin has shown promise as a neuroprotective agent in animal and human models, both alone and together with hypothermia.

Keywords: neonate, brain injury

Perinatal asphyxia
Lack of oxygen and tissue perfusion in the perinatal period can lead to neonatal hypoxic-ischemic encephalopathy (HIE), which occurs in one to three/1,000 live births in developed countries. In 2008, it was estimated that birth asphyxia caused between 563,000 and 997,000 deaths worldwide, 9% of all deaths in children younger than 5 years of age. Recently, therapeutic hypothermia has proven to be effective at improving mortality and neurodevelopmental outcomes in infants with moderate-to-severe HIE. However, even with therapeutic hypothermia, HIE still causes significant morbidity and mortality, with approximately 48% of infants dying or having major neurodevelopmental disability at 18 months of age. Additional interventions are clearly needed to further improve outcomes, and these must be tested in the context of therapeutic hypothermia.

Mechanisms of brain injury
Perinatal asphyxia results from disruption in cerebral perfusion and oxygenation, often caused by an interruption in blood flow and gas exchange across the placenta. The resulting brain injury is characterized by an evolving process, which spans the period of initial interruption of blood flow through the period of recovery after reperfusion. The first phase occurs during the period of decreased oxygen delivery to the infant. The body must switch to anaerobic metabolism, resulting in significantly less adenosine
triphosphate (ATP) being generated for each molecule of glucose metabolized. The decreased availability of ATP causes failure of the ATP-dependent Na+/K+ pump, leading to a sodium influx into cells. The sodium influx is followed by chloride and water influx, leading to cellular swelling and, eventually, lysis with cell death by necrosis.3 The failure of the ATP-dependent Na+/K+ pump also causes membrane depolarization, leading to increased glutamate release and decreased glutamate uptake. The increased concentration of extracellular glutamate, along with activation of ion-gated calcium channels and failure of energy-dependent processes of calcium removal from the cell, causes accumulation of calcium in the cytosol, which has significant negative effects including membrane injury, generation of free radicals and nitric oxide, and further decreases in ATP production.5,6 The number of cells that die during this initial phase is related to the severity of the insult, with a higher number of cells dying in the initial phase after a more severe insult.6 The next phase consists of secondary energy failure that occurs 6 to 48+ hours after the original injury and involves inflammation, cytotoxic edema, nitric oxide synthesis, mitochondrial dysfunction, and further accumulation of excitotoxins.6,7 This phase correlates best with neurodevelopmental outcomes and has the potential to be affected by neuroprotective interventions.5,6,8 Hypoxia and ischemia can cause injury to both white and gray matter regions, depending on the type, duration, timing, and other circumstances of the injury. In term infants, the most common patterns of injury include watershed injury (plus cortical gray matter injury when severe), deep gray matter injury (involving deep grey nuclei, hippocampi, and perirlandic cortex, with additional cortical damage when severe), and multicystic encephalopathy in infants who experience an acute event superimposed on more chronic mild-to-moderate hypoxia.9

Mechanisms of cell death

Three mechanisms of cell death can occur in response to hypoxic-ischemic injury: necrosis, apoptosis, and autophagy. These cell death programs are complex, interrelated, and involve signaling pathways which can potentially be interrupted or modified, allowing for targeted neuroprotective strategies.10 Necrotic cell death tends to occur early following HIE. It is characterized by profound cellular swelling leading to cell rupture, membrane disintegration, and release of intracellular contents.5 Necrotic cell death requires less energy than apoptosis or autophagy, but still involves activation of specific signaling pathways.11,12 Neuronal necrosis that occurs in the context of excitotoxicity and hypoxic-ischemic injury is mediated by membrane depolarization caused by glutamate-triggered influx of calcium into the cell. Necrosis occurs predominantly in sites of profound energy deprivation, such as the core of an ischemic region, and is responsible for much of the immediate cell death during the first phase after injury, but there is a continuum between necrotic and apoptotic cell death.13,14 In contrast to necrosis, apoptosis is a form of programmed cell death characterized by immunologically silent cell shrinkage with nuclear pyknosis and intact plasma membranes.5 It can be activated by intrinsic or extrinsic pathways. The intrinsic, or mitochondrial, pathway depends on the balance of antiapoptotic proteins (such as Bcl-2 and Bcl-xL) and proapoptotic proteins (such as BAX and BAD).15,16 Apoptosis can also be triggered by external signals such as Fas ligand and tumor necrosis factor-alpha (TNF-α) activation of proapoptotic receptors on the cell surface, which is known as the extrinsic pathway. Proapoptotic proteins cause permeabilization of the mitochondrial membrane, allowing factors including cytochrome c to be released into the cytosol, leading to apoptosis.17 Neuroapoptosis following hypoxic-ischemic injury typically occurs in the ischemic penumbra during the secondary phase of brain injury, making this pathway an excellent target for neuroprotection.10,18

Autophagy is a homeostatic process by which unwanted proteins and damaged organelles are eliminated from cells. It is a catabolic process involving intracellular degradation of cytosolic proteins and organelles by autophagosomes, which fuse with lysosomes to form autolysosomes.10 Autophagy is now recognized as a distinct mechanism of cell death that is interrelated to both necrosis and apoptosis.19 There are several proposed mechanisms for the role of autophagy in cell death following hypoxic-ischemic injury, including as an independent mechanism and as a trigger for apoptotic cell death.10

The mechanism of cell death that predominates in hypoxic-ischemic injury is influenced by characteristics of the individual including age (neonates are more sensitive to apoptosis than adults, and the location of calcium permeable membrane receptors switches from white matter to gray matter over time), sex (different specific pathways predominate in males compared to females), and other factors, such as energy availability.20–22 Many cells die from hybrids of multiple pathways (such as apoptosis and necrosis or apoptosis and autophagy), as there are significant interconnections between pathways.23,24 The overlap in cell death pathways makes identifying targets for neuroprotective agents complex, because cell death can proceed down an alternative pathway if one pathway is inhibited.10 Each pathway is important for normal development, thus blocking all pathways completely
can have negative effects.\textsuperscript{25–28} As understanding of the complex interactions between mechanisms of cell death and survival improves, neuroprotective strategies may include use of multiple complimentary agents, either to target different pathways or to use one drug to extend the therapeutic window for another.

**Therapeutic hypothermia**

Therapeutic hypothermia has become the standard of care treatment for HIE.\textsuperscript{3,29} It has multiple neuroprotective effects, including decreased energy depletion, inhibition of glutamate release and decreased impairment in glutamate reuptake, deceased free radical generation and inflammation, and blockade of pathways leading to apoptosis (Figure 1).\textsuperscript{3} It has been shown in trials to reduce the risk of death or major neurodevelopmental disability by approximately 50% with a number needed to treat of 7–9.\textsuperscript{3,30} As hypothermia has become the standard of care, research into other neuroprotective agents, particularly in humans but also in animal models, has shifted from study of a neuroprotective agent alone to investigation of the combined effects of the agent along with hypothermia.

**Erythropoietin**

Erythropoietin (Epo) is a 30.4 kDa hematopoietic cytokine that was originally recognized for its role in erythropoiesis. It is produced primarily in the kidney of adults and the liver of fetuses, although Epo production also occurs in the brain, testis, and placenta.\textsuperscript{31,32} Endogenous Epo is required for normal brain development, function, and repair. Epo is primarily produced by astrocytes but can also be detected in oligodendrocytes, neurons, endothelial cells, and microglia.\textsuperscript{33–38} In the setting of hypoxia-ischemia, Epo receptors (EpoRs) in neurons, astrocytes, and microglia are massively upregulated.\textsuperscript{39,40} Increased Epo expression follows, via hypoxia-mediated stabilization of neuronal transcription factor hypoxia-inducible factor 1α, if the insult is of sufficient duration.\textsuperscript{41,42} Hypoxia-inducible factor-2 (HIF-2) has also been found to regulate the production of Epo in response to hypoxia in many tissues, though its precise role is less clear.\textsuperscript{43–46} In the absence of Epo–EpoR binding, cells are predisposed to apoptosis, while, in the presence of Epo, cells are preserved.\textsuperscript{47,48} This creates an important rationale for exogenous Epo administration, given that brain injury can occur after brief but catastrophic insults, such as placental abruption or cord accidents, which are insufficient to stimulate an increase in endogenous Epo synthesis.\textsuperscript{49}

**Mechanisms of action of Epo**

Epo binds to the EpoR homodimer, which activates Jak2 kinase to phosphorylate Jak2 and EpoR (Figure 2).\textsuperscript{50–52}
This activates multiple signaling cascades, including MAPK/ERK, PI3K/Akt, Stat5, and NF-κB. NF-κB and Stat5 move into the nucleus and act as transcription factors in the production of Bcl-2 and Bcl-xL, which are antiapoptotic proteins. Epo also inhibits the function of Bax and Bad, which are proapoptotic, via AKT. The balance of these proteins determines whether a cell undergoes apoptosis.

Epo appears to have both acute and long-term effects following brain injury (Figure 1). Through multiple mechanisms, Epo decreases cell death acutely and also promotes cell and tissue repair, affecting many components of the neurovascular unit. Many studies have demonstrated Epo’s antiapoptotic effects. Additionally, Epo has also been shown to have anti-inflammatory, neurotropic, and antioxidant properties, along with having a role in promoting angiogenesis, neurogenesis, and oligodendrogenesis.

Epo may protect the brain from edema by upregulation of aquaporin channels. Epo also increases reticulocytosis in preterm infants, which in turn increases iron utilization. When iron is unbound, it can produce free radicals that cause oxidative injury, so, by increasing iron utilization, Epo may secondarily decrease injury.

**Animal and human studies of Epo**

The effects of Epo on neonatal brain injury have been studied in multiple animal models (Table 1), most commonly in the rat model of unilateral carotid ligation followed by hypoxia (Vannucci model) and the middle cerebral artery occlusion model. These models are commonly used to produce gray matter injury similar to that seen in term infants who experience hypoxic-ischemic injury or perinatal stroke, respectively. Animal models have been used both to demonstrate Epo’s neuroprotective effects on gross and histological brain injury and neurobehavioral outcomes and to elucidate the mechanism of neuroprotection. There is some variability in the results of these studies, likely related to variability in methodology, including duration of hypoxia/ischemia; timing, dose, and frequency of Epo administration; and timing of the outcome studied. Overall, however, Epo has been shown...
Table 1 Neonatal animal studies of Epo

<table>
<thead>
<tr>
<th>Animal/age/injury</th>
<th>Dose of Epo/route/timing</th>
<th>Outcomes/results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypoxia/ischemia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse/P7/unilateral carotid ligation, 50 m 10% O₂</td>
<td>1,000 or 5,000 U/kg ip 1 hour prior to injury</td>
<td>Reduction in injury at 1 day in cortex, striatum, hippocampus, and thalamus with 5,000 U/kg and at a dose-related reduction in injury at 7 days in cortex, striatum, and thalamus</td>
<td>113</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2.5 h 8% O₂</td>
<td>1,000 U/kg ip after hypoxic period complete</td>
<td>Decreased mean infarct volume; decrease in apoptotic cells at 72 hours post-injury</td>
<td>114</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1 h 8% O₂</td>
<td>2,000 U/kg ip 10 minutes prior to hypoxia</td>
<td>Reduced brain damage severity and prevented apoptosis at 4 days post-injury; improved short-term functional brain recovery at 24 hours post-injury</td>
<td>115</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2.5 h 8% O₂</td>
<td>1,000 U/kg ip after hypoxic period complete</td>
<td>Less macroscopic brain injury, larger brain volume in injured hemisphere, and improvement in hippocampal CA1 neuronal density at 21 weeks; improvement on spatial memory testing at 22 days and 21 weeks</td>
<td>116</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 50 m 7.7% O₂</td>
<td>10,000 U/kg Epo or 0.08 mg/kg asialoEpo 4 hours prior to injury</td>
<td>Both significantly reduced infarct volumes; asialoEpo reduced activation of ERK</td>
<td>117</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O₂</td>
<td>2,500 U/kg sq at time of injury and 1 and 2 days after injury</td>
<td>Protected dopamine neurons in substantia nigra, pars compacta, and ventral tegmental areas; reduced sensory neglect and prevented rotational asymmetry on behavioral testing at 3 weeks post-injury; no difference in hematocrit, white blood cell, neutrophil, or platelet counts</td>
<td>118</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O₂</td>
<td>300 U ip 24 hours prior to hypoxia and then daily for 2 days</td>
<td>Prevented mortality during hypoxia; increased brain weight at multiple time points; inhibited apoptosis at 24–72 hours post-injury</td>
<td>60</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2.5 h 8% O₂</td>
<td>1,000 U/kg ip after hypoxic period complete</td>
<td>Increased glutathione peroxidase activity at 24 hours post-injury</td>
<td>75</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1 h 8% O₂</td>
<td>2,000 U/kg ip after hypoxic period complete</td>
<td>Improved recovery of sensorimotor function; reduction in extension of brain injury with preservation of cerebral cortex at 35 days post-injury</td>
<td>119</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O₂</td>
<td>5,000 U/kg ip 24, 48, and 72 hours after injury</td>
<td>Increased brain weight at 1, 2, and 3 weeks post-injury; attenuated HI-induced leukocyte infiltration and increases in IL-1β mRNA and protein levels in first 2 weeks post-injury</td>
<td>79</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2.5 h 8% O₂</td>
<td>1,000 U/kg ip after hypoxic period complete</td>
<td>Reversed HI-induced upregulation of proapoptotic BAX and DPS mRNA at 4 hours post-injury; reversed HI-induced downregulation in antipapoptotic Bcl-2 transcription at 24 hours post-injury; reduced mean infarct volume, decreased number of apoptotic cells, reduced bax, and increased Bcl-2 protein expression at 48 hours post-injury</td>
<td>120</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2 h 8% O₂</td>
<td>300 U/kg ip after hypoxic period complete</td>
<td>Attenuated HI-induced impairment in rapid auditory processing and decrease in size of cortex and hippocampus at 2–3 weeks post-injury</td>
<td>121</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 130 m 8% O₂</td>
<td>500, 1,000, or 2,000 U/kg ip 20 minutes after hypoxia, repeated at 2, 4, and 6 days post-injury</td>
<td>1,000 U/kg reduced tissue volume loss in cortex and striatum at 7 days post-injury without stimulating erythropoiesis (measured at 4 weeks post-injury), enhanced functional revascularization, increased progenitor cell migration and neuronal replacement in ischemic areas, and reversed HI-induced sensorimotor changes seen in 4 weeks post-injury</td>
<td>78</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2 h 8% O₂</td>
<td>300 or 1,000 U/kg ip after hypoxic period complete</td>
<td>Both doses decreased histological evidence of brain damage 11 weeks post-injury and improved rapid auditory processing and both spatial and nonspatial learning/memory at different time points from 2–11 weeks post-injury</td>
<td>122</td>
</tr>
<tr>
<td>Rat/P7/1.5 h 8% O₂ with or without unilateral carotid ligation</td>
<td>2,500 U/kg sq at 0, 24, and 48 hours after hypoxic period complete</td>
<td>Prevented HI-induced impairment of adult memory; protected dopaminergic neurons in substantia nigra, pars compacta, and ventral tegmental area (seen on histology performed in adulthood); prevented hypoxia-induced growth delay at 1 and 10 days post-injury; and improved forelimb strength at 10 days post-injury</td>
<td>123</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Animal/age/injury</th>
<th>Dose of Epo/route/timing</th>
<th>Outcomes/results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>250, 2,500, or 5,000 U/kg ip or sq within 30 minutes of hypoxia exposure</td>
<td>Intrapertoneal injection produced a faster and higher peak concentration in the plasma than subcutaneous injection. Hypoxia did not induce detectable levels of endogenous Epo, but exogenous Epo did cross the blood–brain barrier in a dose-dependent manner, peaking at 10 hours and remaining detectable for more than 20 hours post-injury</td>
<td>124</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>2,500, 5,000, or 30,000 U/kg sq daily started after hypoxia for 1, 3, or 7 days</td>
<td>Improvement in HI-induced decrease in antiapoptotic Bcl-2 expression and increase in proapoptotic Bax, improved hearing threshold to similar to that of control animals; reduced apoptotic changes in brain stem and forelimb asymmetry on behavioral testing at 2 weeks post-injury</td>
<td>62</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>3,000 U/kg ip at 0, 24, and 48 hours after hypoxia</td>
<td>DFO + Epo decreased apoptotic cells, but neither DFO, Epo, nor DFO-Epo improved gray or white matter damage or dopaminergic neuronal integrity at 72 hours post-injury</td>
<td>125</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1,000 U/kg ip at 0, 24, and 48 hours after hypoxia</td>
<td>Attenuated HI-induced decrease in antiapoptotic Bcl-2 expression and increase in proapoptotic Bax, caspase-3, and Bax:Bcl-2 ratio at 7 days post-injury</td>
<td>69</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1,000 U/kg ip on days 2, 4, 6, 9, and 13 after hypoxia</td>
<td>No reduction in brain volume loss but did increase oligodendrogenesis, maturation of oligodendrocytes, attenuate white matter injury, enhance neurogenesis, and improve behavioral outcomes between 5 and 14 days after injury</td>
<td>127</td>
</tr>
<tr>
<td>Rat/P7 or P8/unilateral carotid ligation, 2 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>30,000 U/kg ip between ligation and hypoxia</td>
<td>Decreased size of brain lesion and ADC value but no change in FA value on MRI 30 minutes post-injury and upregulated water channel protein aquaporin-4 within hours after injury, indicating Epo may improve clearance of brain edema</td>
<td>81</td>
</tr>
<tr>
<td>Mouse/P9/unilateral carotid ligation, 45 m 10% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>5,000 or 20,000 U/kg at 0, 24, and 48 hours after hypoxia</td>
<td>5,000 U/kg increased progenitor cell proliferation at 72 hours post-injury and improved sensorimotor function, reduced atrophy of the striatum and volume of hippocampal lesion, and improved myelination at 4 and 9 weeks post-injury in female mice only</td>
<td>128</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1,000 U/kg at 0, 24, and 168 hours after hypoxia with or without hypothermia ×8 hours</td>
<td>No differences in behavioral outcomes or histopathologic brain damage scores at 2 or 6 weeks post-injury other than difference in brain injury score in male rats treated with Epo alone</td>
<td>86</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>5,000 U/kg ip at 0, 24, and 48 hours after hypoxia with or without hypothermia ×3 hours</td>
<td>Epo and hypothermia improved sensorimotor function at 2 and 5 weeks post-injury with more improvement in females; hypothermia interacted with sex in affecting outcomes, with only hypothermia and not Epo improving histological outcomes at 5 weeks post-injury</td>
<td>87</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 2 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1,000 U/kg ip at 0, 60, or 180 minutes after hypoxia</td>
<td>Immediate dosing improved defects in rapid auditory processing in juveniles and adults and reduced ventriculomegaly seen on histology in adults associated with HI, but dosing delayed 180 minutes did not, and 60-minute delayed dosing had intermediate effects</td>
<td>129</td>
</tr>
<tr>
<td>Rat/P10/unilateral carotid ligation, 2.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Epo or nanoEpo 30, 100, 300 U/kg, or Epo 5,000 U/kg ip 1 hour after hypoxia, repeated at 24 and 48 hours post-injury</td>
<td>For Epo, only 5,000 U/kg significantly decreased infarct volume at 72 hours post-injury, whereas 100 and 300 U/kg nanoEpo both significantly decreased infarct volume, with 300 U/kg approximating the effect of 5,000 U/kg Epo and both approximating sham surgery animals; similar effects seen on neurobehavioral testing at 3 weeks post-injury and brain weight analysis 4 weeks post-injury</td>
<td>130</td>
</tr>
<tr>
<td>Rat/P7/unilateral carotid ligation, 1.5 h 8% O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1,000 U/kg ip after hypoxia</td>
<td>Improved hearing threshold similar to that of control animals; reduced apoptotic changes in brain stem structures, organ of Corti, spiral ganglion cells, and temporal lobe neurons at 6 weeks post-injury</td>
<td>67</td>
</tr>
<tr>
<td>Rat/P10/MCAO</td>
<td>Either 1,000 U/kg ip ×1 15 minutes after injury or 100, 1,000, or 5,000 U/kg/dose daily ×3 starting 15 minutes after injury</td>
<td>Decreased infarction volume and area at 1 and 3 days post-injury, with 1,000 U/kg being the most effective dose. 1,000 U/kg ×3 regimen reduced number of apoptotic cells in ischemic cortex. No effect on Epo receptor expression in the ischemic cortex. Prevented injury-induced decrease in phosphorylated Jak2 and Stat5 expression; increased antiapoptotic Bcl-X and expression; and had no effect on NF-kB at 1 and 3 days post-injury</td>
<td>52</td>
</tr>
</tbody>
</table>
Rat/P7/MCAO 1,000 U/kg ip at 15 minutes, 1 day, and 2 days post-injury

Rat/P10/MCAO ×45 minutes Epo 5,000 U/kg ×1 after injury

Rat/P10/MCAO ×45 minutes Epo, either 5,000 U/kg ×1 after injury or 1,000 U/kg ×3 (after injury and at 1 and 7 days post-injury)

Rat/P7/MCAO after injection of Lentivirus to label subventricular zone cells at PI

In utero ischemia (prenatal or term)

Monkey/P0 (term)/umbilical cord occlusion Either 3,500 U/kg at 30 minutes of life followed by 2,500 U/kg at 24, 48, and 168 hours or 1,000 U/kg at 30 minutes and 24, 48, and 168 hours, all IV, plus hypothermia >72 hours

Increased brain weight at 6 and 12 weeks post-injury, decreased infarct volume at 6 weeks (greater effect in females than males), increase in size of lesion by 12 weeks in Epo-treated males but not females, improved neurobehavioral outcomes at 6 and 12 weeks post-injury (again greater effect in females) Decreased tissue loss overall in brain, decreased number of astrocytes, and increased neurogenesis in damaged striatum, without changes in subventricular zone volume or density of newly generated cells in injured striatum at 6 weeks post-injury

Three-dose regimen of Epo significantly improved spatial memory and vision and motor-based function and showed nonsignificant trends toward improvement in other behavioral tests at 3 months post-injury; reduced tissue loss and increased neocortex, visual cortex, striatum, and hippocampus volumes at 3–4 months post-injury

Increased subventricular zone neural stem cell lineage cells in injured striatum and neural stem cell-derived neurogenic activity, increased oligodendrocyte precursors, and decreased astrocytes in striatum at 6 weeks post-injury

Prevented death and moderate-to-severe cerebral palsy (assessed through 9 months post-injury); improved motor and cognitive responses, cerebellar growth, and DTI measures on MRI without adverse drug reactions or changes in hematology, liver, or kidney laboratory values

Abbreviations: ADC, apparent diffusion coefficient; asialoEpo, asialoerythropoietin; bax, Bcl-2-associated X protein; Bel-2, B-cell lymphoma 2; Bel-xL, B-cell lymphoma-extra large; DFO, desferoxamine; DTI, diffusion tensor imaging; Epo, erythropoietin; ERK, extracellular signal-related kinase; FA, fractional anisotropy; HI, hypoxia-ischemia; IL-1β, interleukin-1beta; ip, intraperitoneal; IV, intravenous; Jak2, Janus kinase 2; MCAO, middle cerebral artery occlusion; MRI, magnetic resonance imaging; nanoEpo, nanoerythropoietin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; sq, subcutaneous; Stat5, signal transducer and activator of transcription 5; P7, postnatal day 7; m, minutes, h, hours.
in motor and cognitive outcomes, cerebellar growth, and diffusion tensor imaging (DTI) measures.

These three studies clearly have disparate results regarding the efficacy of both hypothermia and Epo. This variability could be related to many factors, including differences in the models used, Epo dosing, and the duration and degree of hypothermia. Traudt’s study is the first study of Epo and hypothermia in a nonhuman primate model of HIE. Large-animal models of brain injury offer both advantages and disadvantages compared to small animal models. Large animals (sheep, piglets, nonhuman primates) are expensive and require more resources for their care, thus it is not possible to include the same number of subjects as are typically included in small-animal studies. However, in many ways, their brains are more similar to those of humans. Large animals possess a gyrencephalic brain, a white to gray matter ratio that better approximates that of humans, and similar vascular patterns to humans and they can be monitored and cared for in a manner similar to neonates in an intensive care unit.

**Human studies of Epo**

In the past 5 years, several studies on the neuroprotective effects of Epo on human infants with HIE have been published (Table 2). The initial study by Zhu et al in 2009 compared Epo to supportive care in infants with moderate-to-severe encephalopathy. Epo was dosed at either 300 or 500 U/kg and given subcutaneously immediately following injury and repeated every other day for 2 weeks intravenously. The authors demonstrated decreased incidence of moderate-to-severe disability or death at 18 months of age in infants given either of the two doses of Epo, particularly in infants with moderate compared to severe HIE, without adverse hematopoietic side effects. The second study, by Elmahdy et al in 2010, compared Epo to supportive care in infants with mild-to-moderate HIE. Epo was dosed at 2,500 U/kg subcutaneously, started within 4–6 hours of injury, and repeated daily for five total doses. These authors also demonstrated improved outcomes in infants treated with Epo, including decreased seizure activity, decreased endogenous nitric oxide production, and improved neurodevelopmental outcomes up to 6 months. The third study, by Wu et al in 2012, was a Phase I/II study of the safety and pharmacokinetics of Epo at escalating doses in infants with HIE being treated with therapeutic hypothermia. Doses ranged from 250 to 2,500 U/kg and were administered intravenously, starting at less than 24 hours of age and continuing every 48 hours for up to six total doses. The authors showed that dosing at 1,000 U/kg produced plasma concentrations similar to those found to be neuroprotective in animals and was well tolerated. At mean age 22 months, infants who received Epo exhibited a relatively low rate of moderate-to-severe disability, even in the setting of significant brain injury. The most recent study, by El Shimi et al in 2014, examined whether a single dose of Epo was as safe and effective as hypothermia in treating HIE, given that hypothermia was not available in many lower-resource nations, despite being the standard of care for HIE in developed nations. Epo was dosed at 1,500 U/kg given subcutaneously on day 1 of life. Hypothermia was accomplished using cold packs to maintain

**Table 2 Human infant studies of Epo**

<table>
<thead>
<tr>
<th>Subjects/treatment groups/type</th>
<th>Dose/timing</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>133 infants with moderate-to-severe HIE (73 given one of two different doses of Epo and 80 controls); randomized trial</td>
<td>Either 300 U/kg or 500 U/kg given every other day for 2 weeks starting &lt;48 hours after birth</td>
<td>Overall improvement in rate of death/moderate-to-severe disability in infants with moderate HIE in Epo groups at 18 months; improvement in behavior as early as day 7; no negative hematopoietic side effects; no difference in outcomes between doses</td>
<td>90</td>
</tr>
<tr>
<td>30 infants with HIE (15 controls and 15 given Epo) plus 15 controls; case-control study</td>
<td>2,500 U/kg given subcutaneously daily for 5 days</td>
<td>Improvement in blood NO concentrations and EEG background; fewer neurologic and developmental abnormalities; no difference in MRI findings</td>
<td>91</td>
</tr>
<tr>
<td>24 infants undergoing hypothermia for HIE given Epo at varying doses (Phase I safety and pharmacokinetics study)</td>
<td>250 U/kg, 500 U/kg, 1,000 U/kg, or 2,500 U/kg given every 48 hours for six doses starting at &lt;24 hours of age</td>
<td>No deaths or serious adverse events; nonlinear pharmacokinetics; plasma concentrations that are neuroprotective in animals seen at 1,000 U/kg dosing</td>
<td>92</td>
</tr>
<tr>
<td>30 infants with perinatal hypoxia (randomized as: ten to supportive care, ten given moderate hypothermia, ten given Epo) and 15 healthy infants; case-control study</td>
<td>Single 1,500 U/kg dose given on day 1 of life</td>
<td>Infants given hypothermia had the best survival, followed by infants given Epo and then the control group, though differences not statistically significant; significantly higher brain-derived neurotrophic factor in hypothermia and Epo groups than in supportive care group</td>
<td>94</td>
</tr>
</tbody>
</table>

**Abbreviations:** EEG, electroencephalography; Epo, erythropoietin; HIE, hypoxic-ischemic encephalopathy; MRI, magnetic resonance imaging; NO, nitric oxide.
a rectal temperature between 33°C and 34°C for 72 hours. This small study showed improved survival in the infants treated with hypothermia compared to single-dose Epo and supportive care, particularly in infants with moderate or Sarnat stage II encephalopathy. There was a trend toward improved MRI brain injury score and functional outcomes in infants treated with hypothermia. Larger Phase III studies to test efficacy are planned or under way in France (Neurepo, NCT01732146), Australia (PAEAN), and the US (NEAT O, NCT01913340).

**Epo dosing and adverse effects**

The optimal dosing regimen in human neonates is unknown. Epo is ineffective at promoting neuroprotection at very low doses and may cause harm at very high doses. Kellert et al’s dose comparison study in rats demonstrated that three doses of 5,000 U/kg resulted in the most consistent neuroprotection with the lowest total dose exposure. Traudt et al’s study, which showed strong benefits of Epo when used in conjunction with hypothermia, found that dosing hypothermic macaques at 1,000 U/kg produced similar pharmacokinetic parameters to rats dosed at 5,000 U/kg. Interestingly, these authors noted that a dosing regimen in hypothermic macaques produced a 25% higher peak Epo concentration than expected based on pharmacokinetic data obtained in normothermic human neonates, suggesting that hypothermia alters Epo’s pharmacokinetics. Wu et al’s pharmacokinetic study of Epo in human neonates undergoing therapeutic hypothermia for HIE also found that 1,000 U/kg of Epo produced similar pharmacokinetic parameters as doses that have been found to be neuroprotective in animal models.

The significance and severity of adverse effects related to Epo administration also remain controversial. As Epo is used primarily as an erythropoietic agent, it certainly has effects on red blood cell formation. Polycythemia has not been seen in trials of neuroprotection in term infants, and two trials did not find a significant difference in hematocrit and number of red blood cell transfusions between treated and untreated infants, although Zhu et al’s trial did show that use of Epo prevented the decrease in hematocrit over time seen in control and hypothermia-only infants. In adults, Epo has been associated with an increased risk for hypertension, but this has not been the case in neonates. In premature infants, Epo has been linked to several possible adverse effects. Early studies demonstrated a risk of neutropenia after treatment with Epo, but this has not been confirmed in later studies of erythropoietic or neuroprotective dosing of preterm infants. There has also been concern about increased risk of retinopathy of prematurity in preterm infants treated with Epo, particularly early in life, but the data are conflicting and this is not relevant to term infants. In one retrospective study, an increased risk of cutaneous hemangiomas was reported with Epo exposure in preterm infants, but, as cutaneous hemangiomas are common in preterm infants, a causal relationship has not been established.

There are theoretical concerns regarding clotting abnormalities in infants treated with both Epo and therapeutic hypothermia. Hypothermia has negative effects on hemostasis and leads to increased risk of disseminated intravascular coagulation. Epo may also affect clot formation, as use of Epo has been associated with increased risk for thromboembolic events in adults with strokes. At this time, no studies of normothermic or hypothermic neonates treated with Epo have demonstrated increased risk of clotting abnormalities, but we must continue to be vigilant about this potential adverse effect. Overall, significant adverse effects have not been seen in term or preterm infants treated with Epo.

**Limitations of studies to date**

**Animal models**

The animal models described previously all attempt to reproduce hypoxic-ischemic injury in term infants. While these models can simulate the human neonatal experience, they are not exact reproductions. Infants that meet clinical criteria for HIE can have had very different antenatal and perinatal experiences. HIE may be caused by a single acute event, such as a placental abruption or umbilical cord prolapse; a more chronic process like intrauterine growth restriction or infection; or a combination of events, such as a difficult delivery in a stressed infant who does not tolerate delivery well due to maternal chorioamnionitis or longstanding placental insufficiency. Thus, infants with HIE who meet entry criteria for a study may in fact have disparate mechanisms of injury, which likely helps to explain variability in response to treatments and, therefore, outcomes. Additionally, it is likely that infants with mild, moderate, and severe HIE will respond differently to neuroprotective therapies. Many of the studies on the neuroprotective effects of Epo following HIE use the Vannucci model, which models acute, severe hypoxic ischemic brain injury, but does not reflect more chronic or combined inflammatory and hypoxic injuries. Thus, it is important to glean information from a wide variety of animal models and, as clinical trials are planned, to target...
neuroprotective therapies toward specific mechanisms of injury that should improve in preclinical trials.

Human studies

There is currently a paucity of human trials available from which to assess the efficacy of Epo neuroprotection for HIE. Phase I/II trials have been undertaken to establish rudimentary safety, pharmacokinetics, and feasibility of larger studies and have provided limited long-term outcome data. Because of the nature of these studies, there is also significant heterogeneity in study design, with Epo doses ranging from 250–2,500 U/kg, dosing intervals ranging from 24–48 hours, and dose numbers ranging from one to seven. Despite these limitations, these studies have laid the groundwork for future Phase III studies in which the safety and efficacy of Epo neuroprotection can be rigorously tested.

Conclusion

In the past 5 years, there has been a significant advancement in treatment of HIE. Therapeutic hypothermia has been proven to improve outcomes, with a number needed to treat of 7. Despite this, infants with moderate-to-severe HIE who receive hypothermia still experience high rates of death (26%) and, among survivors, developmental delay (23%), cerebral palsy (19%), deafness (4%), and blindness (6%). The overall rate of death or major disability despite hypothermia thus remains unacceptably high (48%). Adjuvant therapies are therefore needed to further improve outcomes.

As we further our understanding of how cells die after neonatal hypoxic-ischemic brain injury, we can develop new neuroprotective strategies that promote or inhibit specific pathways. The complex and interconnecting pathways of cell death illustrate the need to approach neuroprotection from multiple angles. Several agents, including Epo, have shown promise as neuroprotective agents and are being studied further. If these therapies interact at different points in tissue response and healing pathways following injury, it is possible that, ultimately, a “cocktail” of therapeutic agents will be used to promote optimal healing.

Disclosure

The authors report no conflicts of interest in this work.

References


